Nathan Cummins, MD
Infectious Disease · Rochester, MNNPI 1225108772
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,519 of the $43,535 with a category attached, or 100.0%. Pfizer accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. 2022 is the largest year on record at $38,080, more than ten times the $16 reported in 2020. Among infectious disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3 payments — averaging $14,512 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$44K
- Insmed, Inc.$16
Across 1 payment — averaging $211,489 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$211K
What the payments were for
- Speaking & faculty fees$43,519100%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 2 | $43,519 |
| Insmed, Inc. | 1 | $16 |
How this compares
$43,535 in reported general payments places this provider in the 95th percentile of 157 infectious disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $453 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Rochester
- Zelalem TemesgenRochester$46K
- Andrew BadleyRochester$22K
- Raymund RazonableRochester$20K
- Marisa AzadRochester$17K
- Priya SampathkumarRochester$13K
- Paschalis VergidisRochester$10K
- Abinash VirkRochester$6K
- Larry BaddourRochester$5K
- Aditya ShahRochester$4K
- Sapna SadaranganiRochester$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.